Galmed PharmaceuticalsGLMD +2.71%27 PB Ratio is 0.24 as of Jun. 24, 2026, which is 76% below its 10-year median of 0.98. GuruFocus rates GLMD with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, Galmed Pharmaceuticals ranks better than 98.05% on this metric.
Galmed Pharmaceuticals Ltd stock PB Ratio (=0.24) is close to 3-year high of 0.24.
The historical rank and industry rank for Galmed Pharmaceuticals's PB Ratio or its related term are showing as below:
GLMD'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.98 Max: 18.23
Current: 0.24
During the past 13 years, Galmed Pharmaceuticals's highest PB Ratio was 18.23. The lowest was 0.01. And the median was 0.98.
GLMD's PB Ratio is ranked better than 98.05% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs GLMD: 0.24
During the past 12 months, Galmed Pharmaceuticals's average Book Value Per Share Growth Rate was -75.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -70.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -63.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -34.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Galmed Pharmaceuticals was 53.40% per year. The lowest was -70.80% per year. And the median was -33.70% per year.
Back to Basics: PB Ratio
Galmed Pharmaceuticals (NAS:GLMD) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Galmed Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galmed Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Galmed Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Galmed Pharmaceuticals (GLMD) has a PB Ratio of 0.24 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Galmed Pharmaceuticals and its competitors. This is 76% below median its historical median of 0.98. Over the past decade, Galmed Pharmaceuticals' PB Ratio has ranged from 0.01 to 18.23. According to the industry distribution chart, Galmed Pharmaceuticals ranks #24 out of 1233 companies in the Biotechnology industry, placing it in the top 1.9%.
Is Galmed Pharmaceuticals' PB Ratio too high?
Galmed Pharmaceuticals' current PB Ratio of 0.24 is 76% below median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 18.23. The Biotechnology industry median PB Ratio is 2.83. Galmed Pharmaceuticals' value of 0.24 is 91.5% below this industry median. Based on the distribution chart, Galmed Pharmaceuticals ranks #24 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Galmed Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' PB Ratio compare to RNAZ and ARTL?
According to the Biotechnology industry distribution chart, Galmed Pharmaceuticals ranks #24 out of 1233 companies for PB Ratio. This places Galmed Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.83. Galmed Pharmaceuticals' value of 0.24 is 91.5% below this benchmark. Historically, Galmed Pharmaceuticals' own PB Ratio has ranged from 0.01 to 18.23 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 2.83, Galmed Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galmed Pharmaceuticals's current PB Ratio of 0.24 is 91.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Galmed Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galmed Pharmaceuticals's current PB Ratio is 0.24, which is 76% below median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current PB Ratio of 0.24. The current PB Ratio is 0.24, which is 76% below median its 10-year median of 0.98 and 91.5% below the Biotechnology industry median of 2.83. Galmed Pharmaceuticals' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current PB Ratio is 0.24 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
27GF Score
Get the complete analysis for GLMD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLMD has been successfully added to your 
